Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

 
• By Sarah Karlin-Smith
sign that reads "false"
Promoting clinical benefits of an interchangeable over standard biosimilars is likely to be considered false and misleading by the FDA. • Source: Shutterstock

More from Marketing & Advertising

More from Compliance